Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: A report from the AIEOP registry

Franca Fagioli, Paola Quarello, Marco Zecca, Edoardo Lanino, Carla Rognoni, Adriana Balduzzi, Chiara Messina, Claudio Favre, Roberto Foà, Mimmo Ripaldi, Sergio Rutella, Giuseppe Basso, Arcangelo Prete, Franco Locatelli

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Children with high-risk acute lymphoblastic leukemia in first complete remission can benefit from allogeneic hematopoietic stem cell transplantation. We analyzed the outcome of 211 children with high-risk acute lymphoblastic leukemia in first complete remission who were given an allogeneic transplant between 1990 and 2008; the outcome of patients who, despite having an indication for transplantation and a suitable donor, did not receive the allograft for different reasons in the same time period was not analyzed. Sixty-nine patients (33%) were transplanted between 1990 and 1999, 58 (27%) between 2000 and 2005, and 84 (40%) between 2005 and 2008. A matched family donor was employed in 138 patients (65%) and an unrelated donor in 73 (35%). The 10-year probabilities of overall and disease-free survival were 63.4% and 61%, respectively. The 10-year cumulative incidences of transplantation-related mortality and relapse were 15% and 24%, respectively. After 1999, no differences in either disease-free survival or transplant-related mortality were observed in patients transplanted from unrelated or matched family donors. In multivariate analysis, grade IV acute graft-versus-host disease was an independent factor associated with worse disease-free survival. By contrast, grade I acute graft-versus-host disease and age at diagnosis between 1 and 9 years were favorable prognostic variables. Our study, not intended to evaluate whether transplantation is superior to chemotherapy for children with acute lymphoblastic leukemia in first complete remission and high-risk features, shows that the allograft cured more than 60% of these patients; in the most recent period, the outcome of recipients of grafts from matched family and unrelated donors was comparable.

Original languageEnglish
Pages (from-to)1273-1281
Number of pages9
JournalHaematologica
Volume98
Issue number8
DOIs
Publication statusPublished - Aug 1 2013

Fingerprint

Hematopoietic Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Registries
Disease-Free Survival
Unrelated Donors
Transplantation
Tissue Donors
Graft vs Host Disease
Transplants
Allografts
Mortality
Multivariate Analysis
Recurrence
Drug Therapy
Incidence

ASJC Scopus subject areas

  • Hematology

Cite this

Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission : A report from the AIEOP registry. / Fagioli, Franca; Quarello, Paola; Zecca, Marco; Lanino, Edoardo; Rognoni, Carla; Balduzzi, Adriana; Messina, Chiara; Favre, Claudio; Foà, Roberto; Ripaldi, Mimmo; Rutella, Sergio; Basso, Giuseppe; Prete, Arcangelo; Locatelli, Franco.

In: Haematologica, Vol. 98, No. 8, 01.08.2013, p. 1273-1281.

Research output: Contribution to journalArticle

Fagioli, Franca ; Quarello, Paola ; Zecca, Marco ; Lanino, Edoardo ; Rognoni, Carla ; Balduzzi, Adriana ; Messina, Chiara ; Favre, Claudio ; Foà, Roberto ; Ripaldi, Mimmo ; Rutella, Sergio ; Basso, Giuseppe ; Prete, Arcangelo ; Locatelli, Franco. / Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission : A report from the AIEOP registry. In: Haematologica. 2013 ; Vol. 98, No. 8. pp. 1273-1281.
@article{00b707bf93fd4289bb8c3d69563e2e45,
title = "Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: A report from the AIEOP registry",
abstract = "Children with high-risk acute lymphoblastic leukemia in first complete remission can benefit from allogeneic hematopoietic stem cell transplantation. We analyzed the outcome of 211 children with high-risk acute lymphoblastic leukemia in first complete remission who were given an allogeneic transplant between 1990 and 2008; the outcome of patients who, despite having an indication for transplantation and a suitable donor, did not receive the allograft for different reasons in the same time period was not analyzed. Sixty-nine patients (33{\%}) were transplanted between 1990 and 1999, 58 (27{\%}) between 2000 and 2005, and 84 (40{\%}) between 2005 and 2008. A matched family donor was employed in 138 patients (65{\%}) and an unrelated donor in 73 (35{\%}). The 10-year probabilities of overall and disease-free survival were 63.4{\%} and 61{\%}, respectively. The 10-year cumulative incidences of transplantation-related mortality and relapse were 15{\%} and 24{\%}, respectively. After 1999, no differences in either disease-free survival or transplant-related mortality were observed in patients transplanted from unrelated or matched family donors. In multivariate analysis, grade IV acute graft-versus-host disease was an independent factor associated with worse disease-free survival. By contrast, grade I acute graft-versus-host disease and age at diagnosis between 1 and 9 years were favorable prognostic variables. Our study, not intended to evaluate whether transplantation is superior to chemotherapy for children with acute lymphoblastic leukemia in first complete remission and high-risk features, shows that the allograft cured more than 60{\%} of these patients; in the most recent period, the outcome of recipients of grafts from matched family and unrelated donors was comparable.",
author = "Franca Fagioli and Paola Quarello and Marco Zecca and Edoardo Lanino and Carla Rognoni and Adriana Balduzzi and Chiara Messina and Claudio Favre and Roberto Fo{\`a} and Mimmo Ripaldi and Sergio Rutella and Giuseppe Basso and Arcangelo Prete and Franco Locatelli",
year = "2013",
month = "8",
day = "1",
doi = "10.3324/haematol.2012.079707",
language = "English",
volume = "98",
pages = "1273--1281",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission

T2 - A report from the AIEOP registry

AU - Fagioli, Franca

AU - Quarello, Paola

AU - Zecca, Marco

AU - Lanino, Edoardo

AU - Rognoni, Carla

AU - Balduzzi, Adriana

AU - Messina, Chiara

AU - Favre, Claudio

AU - Foà, Roberto

AU - Ripaldi, Mimmo

AU - Rutella, Sergio

AU - Basso, Giuseppe

AU - Prete, Arcangelo

AU - Locatelli, Franco

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Children with high-risk acute lymphoblastic leukemia in first complete remission can benefit from allogeneic hematopoietic stem cell transplantation. We analyzed the outcome of 211 children with high-risk acute lymphoblastic leukemia in first complete remission who were given an allogeneic transplant between 1990 and 2008; the outcome of patients who, despite having an indication for transplantation and a suitable donor, did not receive the allograft for different reasons in the same time period was not analyzed. Sixty-nine patients (33%) were transplanted between 1990 and 1999, 58 (27%) between 2000 and 2005, and 84 (40%) between 2005 and 2008. A matched family donor was employed in 138 patients (65%) and an unrelated donor in 73 (35%). The 10-year probabilities of overall and disease-free survival were 63.4% and 61%, respectively. The 10-year cumulative incidences of transplantation-related mortality and relapse were 15% and 24%, respectively. After 1999, no differences in either disease-free survival or transplant-related mortality were observed in patients transplanted from unrelated or matched family donors. In multivariate analysis, grade IV acute graft-versus-host disease was an independent factor associated with worse disease-free survival. By contrast, grade I acute graft-versus-host disease and age at diagnosis between 1 and 9 years were favorable prognostic variables. Our study, not intended to evaluate whether transplantation is superior to chemotherapy for children with acute lymphoblastic leukemia in first complete remission and high-risk features, shows that the allograft cured more than 60% of these patients; in the most recent period, the outcome of recipients of grafts from matched family and unrelated donors was comparable.

AB - Children with high-risk acute lymphoblastic leukemia in first complete remission can benefit from allogeneic hematopoietic stem cell transplantation. We analyzed the outcome of 211 children with high-risk acute lymphoblastic leukemia in first complete remission who were given an allogeneic transplant between 1990 and 2008; the outcome of patients who, despite having an indication for transplantation and a suitable donor, did not receive the allograft for different reasons in the same time period was not analyzed. Sixty-nine patients (33%) were transplanted between 1990 and 1999, 58 (27%) between 2000 and 2005, and 84 (40%) between 2005 and 2008. A matched family donor was employed in 138 patients (65%) and an unrelated donor in 73 (35%). The 10-year probabilities of overall and disease-free survival were 63.4% and 61%, respectively. The 10-year cumulative incidences of transplantation-related mortality and relapse were 15% and 24%, respectively. After 1999, no differences in either disease-free survival or transplant-related mortality were observed in patients transplanted from unrelated or matched family donors. In multivariate analysis, grade IV acute graft-versus-host disease was an independent factor associated with worse disease-free survival. By contrast, grade I acute graft-versus-host disease and age at diagnosis between 1 and 9 years were favorable prognostic variables. Our study, not intended to evaluate whether transplantation is superior to chemotherapy for children with acute lymphoblastic leukemia in first complete remission and high-risk features, shows that the allograft cured more than 60% of these patients; in the most recent period, the outcome of recipients of grafts from matched family and unrelated donors was comparable.

UR - http://www.scopus.com/inward/record.url?scp=84881002770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881002770&partnerID=8YFLogxK

U2 - 10.3324/haematol.2012.079707

DO - 10.3324/haematol.2012.079707

M3 - Article

C2 - 23445874

AN - SCOPUS:84881002770

VL - 98

SP - 1273

EP - 1281

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -